Literature DB >> 9815846

Angiogenic protein expression in advanced epithelial ovarian cancer.

D P Barton1, A Cai, K Wendt, M Young, A Gamero, S De Cesare.   

Abstract

We set out to determine whether advanced epithelial ovarian cancer (EOC) is associated with elevated serum and ascitic concentrations of the angiogenic factors angiogenin (ANG), basic fibroblastic growth factor (bFGF), and vascular endothelial growth factor (VEGF), and whether the expression of angiogenic factors was associated with tumor vascularity. Serum and ascitic samples were collected from previously untreated patients with FIGO stage III and IV EOC and stored at -70 degreesC. Levels of the three factors were determined by enzyme-linked immunoassay. Histological sections from paraffin blocks of ovarian cancers were stained immunochemically for factor VIII, CD34, and VEGF. Thirty-nine patients were studied, although not all had paired serum and ascitic samples. For each angiogenic factor, the following findings were noted: (a) there was a wide range in serum and ascitic fluid concentrations; (b) the mean serum concentration was higher (P < 0.05) than the mean concentration in normal serum; and (c) the mean serum concentration was lower (P < 0. 05) than the mean ascitic concentration. Overall, the most consistent pattern of elevated serum and ascitic concentrations was with bFGF. With serum samples, 38.9% of patients had a normal VEGF concentration, as did 15.3% for ANG and 7.7% for bFGF. In ascites, the VEGF concentration was in the range for normal serum in 24.5% of samples, compared to 39.4% for ANG and 2.8% for bFGF. In paired samples, both VEGF and bFGF showed higher ascitic concentrations in 100 and 88.3% of samples, compared to 53.3% for ANG. There was no correlation between the serum and/or ascitic concentration of one factor and that of another, suggesting that these factors are independently regulated. Staining with anti-CD34 was more sensitive and reliable than with anti-factor VIII. VEGF staining was most prominent in poorly differentiated tumors and was observed only on tumor cells. There was no correlation between the serum or ascitic concentrations of angiogenic factors and tumor vascularity. Advanced EOC is associated with raised serum and ascitic bFGF concentrations and with markedly elevated ascitic VEGF in most cases. Serum VEGF and serum and ascitic ANG are less often elevated. There was no correlation between the angiogenic profile in serum and ascites and tumor vascularity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815846

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma.

Authors:  Qi Niu; Zhao-You Tang; Zeng-Chen Ma; Lun-Xiu Qin; Lian-Hai Zhang
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

2.  A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells.

Authors:  H Naora; Y Q Yang; F J Montz; J D Seidman; R J Kurman; R B Roden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Ultrastructural immunolocalization of basic fibroblast growth factor in endothelial cells: morphologic evidence for unconventional secretion of a novel protein.

Authors:  Ranan Gulhan Aktas; Robert J Kayton
Journal:  J Mol Histol       Date:  2011-08-10       Impact factor: 2.611

4.  A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation.

Authors:  Norie Yoshioka; Li Wang; Koji Kishimoto; Takanori Tsuji; Guo-fu Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

5.  L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.

Authors:  Feng Gao; Sergio X Vasquez; Feng Su; Svetlana Roberts; Neha Shah; Victor Grijalva; Satoshi Imaizumi; Arnab Chattopadhyay; Ekambaram Ganapathy; David Meriwether; Brad Johnston; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Integr Biol (Camb)       Date:  2011-02-01       Impact factor: 2.192

6.  Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

Authors:  Limin Hu; Judith Hofmann; Charles Zaloudek; Napoleone Ferrara; Thomas Hamilton; Robert B Jaffe
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

7.  Normal and SV40 transfected human peritoneal mesothelial cells produce IL-6 and IL-8: implication for gynaecological disease.

Authors:  X Y Zhang; M Guckian; N Nasiri; P A Lovell; A G Dalgleish; D P J Barton
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 8.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 9.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

10.  A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2.

Authors:  Fumikata Hara; Shaija Samuel; Jinsong Liu; Daniel Rosen; Robert R Langley; Honami Naora
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.